Login to Your Account

Heptares' GPCR Platform Lands Cubist Collaboration

By Nuala Moran
Staff Writer

Wednesday, January 9, 2013
Heptares Therapeutics Ltd. convinced another partner of the power of its G protein-coupled receptor (GPCR) technology, sealing a deal with Cubist Pharmaceuticals Inc. around one – or possibly two – targets to be nominated by the quoted U.S. biotech.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription